NextFin news, On Thursday, October 2, 2025, President Donald Trump announced a postponement of the planned 100% tariffs on imported branded or patented pharmaceutical drugs, which were scheduled to take effect on October 1. The tariffs were intended to apply to drugs imported primarily from China and India, the leading global drug manufacturers.
Trump initially declared the tariffs via a post on his social media platform, Truth Social, stating that the tariffs would be imposed unless companies were actively building pharmaceutical manufacturing plants in the United States. The administration defined "building" as either "breaking ground" or "under construction." However, as of October 1, the tariffs have been put on hold amid ongoing discussions and government shutdown complications.
The White House indicated that the tariffs would eventually target companies that do not invest in U.S. manufacturing capacity or fail to agree to lower drug prices in the American market. Several pharmaceutical companies, including AbbVie, Genentech, and Johnson & Johnson, have recently begun expanding manufacturing operations in the U.S.
Alongside the tariff delay, President Trump announced new efforts to reduce prescription drug costs for American consumers. Notably, Pfizer agreed to lower prices for certain drugs under the Medicaid program. Additionally, the Pharmaceutical Research and Manufacturers of America (PhRMA) revealed plans to launch a website called AmericasMedicines.com in January 2026, enabling consumers to purchase medicines directly from manufacturers, potentially at significant discounts.
Trump also introduced TrumpRx, a forthcoming platform designed to allow consumers to buy prescription drugs directly from manufacturers at an average discount of 50%. Details about the participating companies and specific drugs available remain limited at this time.
Experts have expressed concerns that imposing high tariffs on imported drugs could increase costs for consumers, especially for generic medications that constitute approximately 90% of U.S. prescriptions. There are worries that such tariffs might lead to drug shortages and force patients to switch to more expensive brand-name drugs, exacerbating affordability issues, particularly for vulnerable populations such as Black Americans who disproportionately suffer from chronic diseases requiring daily medication.
Pharmacy industry representatives have cautioned that tariffs could negatively impact independent pharmacies and patients relying on Medicare, as reimbursement rates may not cover increased costs. The administration has exempted generic drugs and pharmaceuticals produced in the European Union and Japan from the 100% tariff, applying instead a capped 15% tariff due to recent trade agreements.
These developments come amid broader efforts by the Trump administration to promote domestic pharmaceutical manufacturing and reduce drug prices, as outlined in a July 31 executive order. The administration's approach balances tariff threats with incentives for companies to invest in U.S. production and negotiate lower prices.
As of October 2, 2025, the situation remains fluid, with the White House continuing to engage with pharmaceutical companies and stakeholders to finalize policies aimed at making prescription drugs more affordable while encouraging domestic manufacturing growth.
Explore more exclusive insights at nextfin.ai.
